Roles of Trained Immunity in the Pathogenesis of Cholangiopathies: A Therapeutic Target
Chao Yan, Stephane Koda, Jing Wu, Bei‐Bei Zhang, Qian Yu, Mihai G. Netea, Ren‐Xian Tang, Kui‐Yang Zheng – 28 May 2020
Burden of Cirrhosis on Patients and Caregivers
Michael L. Volk – 28 May 2020
Protective and Detrimental Roles of p38α Mitogen‐Activated Protein Kinase in Different Stages of Nonalcoholic Fatty Liver Disease
Seonghwan Hwang, Xiaolin Wang, Robim M. Rodrigues, Jing Ma, Yong He, Wonhyo Seo, Seol Hee Park, Seung‐Jin Kim, Dechun Feng, Bin Gao – 28 May 2020
Lipid Remodeling in Hepatocyte Proliferation and Hepatocellular Carcinoma
Zoe Hall, Davide Chiarugi, Evelina Charidemou, Jack Leslie, Emma Scott, Luca Pellegrinet, Michael Allison, Gabriele Mocciaro, Quentin M. Anstee, Gerard I. Evan, Matthew Hoare, Antonio Vidal‐Puig, Fiona Oakley, Michele Vacca, Julian L. Griffin – 27 May 2020
Microsteatosis in Livers From Donation After Circulatory Death Donors Is Associated With Inferior Outcomes Following Liver Transplantation
Natalie M. Bath, Glen Leverson, David P. Al‐Adra, Anthony M. D’Alessandro, Joshua D. Mezrich, David P. Foley – 26 May 2020 – The acceptable threshold remains unknown for the percentage of macrosteatosis (MaS) and microsteatosis (MiS) to yield optimal outcomes after donation after circulatory death (DCD) liver transplantation (LT). The purpose of this analysis was to determine the impact of donor liver MaS and MiS on DCD LT outcomes.
Unraveling the Relationship Between Itching, Scratch Scales, and Biomarkers in Children With Alagille Syndrome
Binita M. Kamath, Cathie Spino, Richard McLain, John C. Magee, Emily M. Fredericks, Kenneth D. Setchell, Alexander Miethke, Jean P. Molleston, Cara L. Mack, Robert H. Squires, Estella M. Alonso, Karen F. Murray, Kathleen M. Loomes, M. Kyle Jensen, Saul J. Karpen, Philip Rosenthal, Danny Thomas, Ronald J. Sokol, Benjamin L. Shneider, for the Childhood Liver Disease Research Network (ChiLDReN) – 26 May 2020 – Pruritus is a debilitating symptom for patients with Alagille syndrome (ALGS).
Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis‐4 Score
Stuart C. Gordon, Nandita Kachru, Emily Parker, Stephanie Korrer, A. Burak Ozbay, Robert J. Wong – 26 May 2020 – Limited evidence exists on the clinical and economic burden of advanced fibrosis in patients with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) due to the invasiveness of liver biopsies for accurately staging liver disease. The fibrosis‐4 (FIB‐4) score allows for noninvasive assessment of liver fibrosis by using clinical and laboratory data alone.
YAP1 Withdrawal in Hepatoblastoma Drives Therapeutic Differentiation of Tumor Cells to Functional Hepatocyte‐Like Cells
Jordan L. Smith, Tomás C. Rodríguez, Haiwei Mou, Suet‐Yan Kwan, Henry Pratt, Xiao‐Ou Zhang, Yueying Cao, Shunqing Liang, Deniz M. Ozata, Tianxiong Yu, Qiangzong Yin, Max Hazeltine, Zhiping Weng, Erik J. Sontheimer, Wen Xue – 26 May 2020
HBV‐RNA Co‐amplification May Influence HBV DNA Viral Load Determination
Benjamin Maasoumy, Anna Maria Geretti, André Frontzek, Harrison Austin, Gudrun Aretzweiler, Monica Garcia‐Álvarez, Susanne Leuchter, Christian O. Simon, Ed G. Marins, Jesse A. Canchola, Markus Cornberg, Rafael Delgado, Heiner Wedemeyer – 26 May 2020 – Despite effective hepatitis B virus (HBV)‐DNA suppression, HBV RNA can circulate in patients receiving nucleoside/nucleotide analogues (NAs).